Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with renal lesions suspicious for renal cell carcinoma (RCC) have a variety of different treatment pathways available to them. Imaging surveillance is being used frequently on smaller renal masses, and radiologists are being asked to biopsy more renal lesions to better guide decision making by urology. This is in large part due to the pathologic grade of renal masses having been shown to correlate with patient outcomes. The World Health Organization (WHO) or Fuhrman grade is the standard grading scale used by pathologists for RCC. The goal of this study will be to correlate contrast enhanced ultrasound findings with the pathologic grade of RCC. Specifically, the investigators hypothesize that tumors with different pathologic grades will show different patterns of qualitative enhancement, as well as different perfusion kinetics.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indiana University

Criteria

Inclusion Criteria:

• Greater than or equal to 18 years of age

• Previously identified renal mass with radiology and clinical features consistent with RCC

• Clinical care plan includes partial or total nephrectomy

Exclusion Criteria:

• Less than 18 years of age

• Currently pregnant

• Renal mass with clinical care plan that does not include nephrectomy

• Renal mass suspected to be non RCC neoplasm by imaging and clinical data

• Renal mass unable to be visualized by grayscale ultrasound

• Known renal vein thrombosis